Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 apalutamide + abiraterone acetate + prednisone vs abiraterone acetate + prednisone in chemotherapy-naive mCRPC
jRCT2080223063Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Apalutamide + abiraterone acetate + prednisone with Placebo + abiraterone acetate + prednisone (2 arms). Started Jan 2016; status: completed.
02
Drugs
apalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2080223063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223063.